MAGLE Stock Overview
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that servs pharmaceutical and medical device industry on a contract basis in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Magle Chemoswed Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr30.20 |
| 52 Week High | kr38.00 |
| 52 Week Low | kr21.40 |
| Beta | 0.59 |
| 1 Month Change | 0.67% |
| 3 Month Change | 18.90% |
| 1 Year Change | 2.03% |
| 3 Year Change | -27.92% |
| 5 Year Change | n/a |
| Change since IPO | 47.25% |
Recent News & Updates
Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26
Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%
Mar 29Recent updates
Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality
Apr 26Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%
Mar 29Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings
Oct 05Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?
Jan 22Shareholder Returns
| MAGLE | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | -0.7% |
| 1Y | 2.0% | 0.6% | 4.4% |
Return vs Industry: MAGLE underperformed the Swedish Life Sciences industry which returned 7% over the past year.
Return vs Market: MAGLE underperformed the Swedish Market which returned 10.3% over the past year.
Price Volatility
| MAGLE volatility | |
|---|---|
| MAGLE Average Weekly Movement | 6.7% |
| Life Sciences Industry Average Movement | 6.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: MAGLE has not had significant price volatility in the past 3 months.
Volatility Over Time: MAGLE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1944 | 78 | Justin Pierce | www.maglechemoswed.com |
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that servs pharmaceutical and medical device industry on a contract basis in Sweden. The company focuses on the process development and manufacture of active pharmaceutical ingredients (API); and research, development, and production of products in the areas of wound care and diagnostics with a focus on products based on degradable starch microspheres. Its APIs include warfarin sodium products that are used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson’s disease.
Magle Chemoswed Holding AB (publ) Fundamentals Summary
| MAGLE fundamental statistics | |
|---|---|
| Market cap | kr326.16m |
| Earnings (TTM) | kr12.23m |
| Revenue (TTM) | kr171.17m |
26.7x
P/E Ratio1.9x
P/S RatioIs MAGLE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAGLE income statement (TTM) | |
|---|---|
| Revenue | kr171.17m |
| Cost of Revenue | kr17.18m |
| Gross Profit | kr153.99m |
| Other Expenses | kr141.76m |
| Earnings | kr12.23m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 18, 2024
| Earnings per share (EPS) | 1.13 |
| Gross Margin | 89.96% |
| Net Profit Margin | 7.14% |
| Debt/Equity Ratio | 36.3% |
How did MAGLE perform over the long term?
See historical performance and comparison